LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 127

Search options

  1. Article: [Current state of treatment for myelodysplastic syndromes].

    Ichikawa, Motoshi

    Rinsho ketsueki] The Japanese journal of clinical hematology

    2023  Volume 64, Issue 9, Page(s) 988–997

    Abstract: Myelodysplastic syndromes (MDS) are hematopoietic stem cell neoplasms characterized by bone marrow failure with a propensity to develop into acute myeloid leukemia (AML). Recent advances in genome-wide analyses have enabled identification of most somatic ...

    Abstract Myelodysplastic syndromes (MDS) are hematopoietic stem cell neoplasms characterized by bone marrow failure with a propensity to develop into acute myeloid leukemia (AML). Recent advances in genome-wide analyses have enabled identification of most somatic gene mutations responsible for MDS, and multiplex gene-panel testing for hematological malignancies will be available soon. Thus, identification of genetic abnormalities is now enabling precise diagnosis and risk-stratification of MDS. Recently, two diagnostic classification systems for MDS have been published as updates to the previous WHO classification of myeloid tumors. The IPSS-M has also been proposed as a new risk-stratification system based on genetic abnormalities and known prognostic factors. Following identification of pathological processes in MDS, therapeutic agents that can alter the course of disease, including azacitidine and lenalidomide, were approved and became available in Japan. Several novel therapeutic agents are under development as well. This paper will discuss updated diagnostic and risk-stratification systems, as well as standard treatment strategies for MDS.
    MeSH term(s) Humans ; Genome-Wide Association Study ; Myelodysplastic Syndromes/therapy ; Myelodysplastic Syndromes/drug therapy ; Lenalidomide/therapeutic use ; Azacitidine/therapeutic use ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/therapy ; Prognosis
    Chemical Substances Lenalidomide (F0P408N6V4) ; Azacitidine (M801H13NRU)
    Language Japanese
    Publishing date 2023-10-04
    Publishing country Japan
    Document type English Abstract ; Journal Article
    ZDB-ID 390900-1
    ISSN 0485-1439
    ISSN 0485-1439
    DOI 10.11406/rinketsu.64.988
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1175: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 535: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: [Updated treatment strategies for myelodysplastic syndromes].

    Ichikawa, Motoshi

    Rinsho ketsueki] The Japanese journal of clinical hematology

    2022  Volume 63, Issue 6, Page(s) 660–666

    Abstract: Myelodysplastic syndromes (MDS) are hematopoietic stem cell neoplasms, which are characterized as bone marrow failure with a propensity to develop acute myeloid leukemia (AML). Patients with MDS tend to be of higher age, with usually poor antineoplastic ... ...

    Abstract Myelodysplastic syndromes (MDS) are hematopoietic stem cell neoplasms, which are characterized as bone marrow failure with a propensity to develop acute myeloid leukemia (AML). Patients with MDS tend to be of higher age, with usually poor antineoplastic chemotherapy response. The life prognosis of MDS is poor, and its curative treatment is limited to allogeneic hematopoietic cell transplantation. Recent advances in hematopoietic cell transplantation, including alternative donors or reduced-intensity conditioning regimens, resulted in an expanded treatment indication for patients of higher age. Moreover, several novel therapeutic agents are implemented after the elucidation of pathological processes in MDS. Therapeutic agents that can alter the disease course, including azacitidine and lenalidomide, are approved and available in Japan. Additionally, other therapeutic agents for MDS, such as erythropoiesis-stimulating agents and oral iron chelators, are also available, and clinical trials for novel agents are also underway. This study discussed the updated risk-stratified treatment strategies for MDS and the development of novel agents.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Azacitidine/therapeutic use ; Hematopoietic Stem Cell Transplantation ; Humans ; Iron Chelating Agents/therapeutic use ; Lenalidomide/therapeutic use ; Leukemia, Myeloid, Acute/drug therapy ; Myelodysplastic Syndromes/drug therapy
    Chemical Substances Antineoplastic Agents ; Iron Chelating Agents ; Lenalidomide (F0P408N6V4) ; Azacitidine (M801H13NRU)
    Language Japanese
    Publishing date 2022-08-17
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 390900-1
    ISSN 0485-1439
    ISSN 0485-1439
    DOI 10.11406/rinketsu.63.660
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1175: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 535: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: [Management of lower-risk myelodysplastic syndromes].

    Ichikawa, Motoshi

    Rinsho ketsueki] The Japanese journal of clinical hematology

    2020  Volume 61, Issue 9, Page(s) 1212–1217

    Abstract: Myelodysplastic syndromes (MDS) are neoplastic diseases of the hematopoietic stem cells, caused by genetic mutations. The clinical courses of MDS are highly variable based on the underlying genetic aberrations, ranging from slowly progressing cytopenia ... ...

    Abstract Myelodysplastic syndromes (MDS) are neoplastic diseases of the hematopoietic stem cells, caused by genetic mutations. The clinical courses of MDS are highly variable based on the underlying genetic aberrations, ranging from slowly progressing cytopenia to rapidly-manifesting fatal diseases, including the development of acute myelogenous leukemia. The management of lower-risk MDS, which is risk-stratified based on the revised International Prognostic Scoring System (IPSS-R), mainly consists of a supportive therapy, including blood transfusion to treat anemia and thrombocytopenia. Recently, three novel drugs were approved, which became available in Japan. These include darbepoetin alfa, an erythropoiesis-stimulating agent; lenalidomide, which is specifically active for anemia of 5q- syndrome; and deferasirox, an oral iron-chelating agent. Decision analyses also provide evidence in determining the optimal timing for the potentially curative allogeneic hematopoietic stem cell transplantation for lower-risk MDS. Thus, the management of lower-risk MDS should be optimized using these novel agents and newly available evidence.
    MeSH term(s) Anemia, Macrocytic ; Darbepoetin alfa ; Humans ; Japan ; Lenalidomide/therapeutic use ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/genetics ; Myelodysplastic Syndromes/therapy ; Risk Assessment
    Chemical Substances Darbepoetin alfa (15UQ94PT4P) ; Lenalidomide (F0P408N6V4)
    Language Japanese
    Publishing date 2020-10-14
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 390900-1
    ISSN 0485-1439
    ISSN 0485-1439
    DOI 10.11406/rinketsu.61.1212
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1175: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 535: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: [Ⅰ.Myelodysplastic Syndromes].

    Ichikawa, Motoshi / Mitani, Kinuko

    Gan to kagaku ryoho. Cancer & chemotherapy

    2019  Volume 46, Issue 5, Page(s) 862–867

    MeSH term(s) Humans ; Myelodysplastic Syndromes
    Language Japanese
    Publishing date 2019-06-12
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 604842-0
    ISSN 0385-0684
    ISSN 0385-0684
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2573: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Pathophysiology of MDS: genomic aberrations.

    Ichikawa, Motoshi

    Rinsho ketsueki] The Japanese journal of clinical hematology

    2016  Volume 57, Issue 10, Page(s) 1972–1979

    Abstract: Myelodysplastic syndromes (MDS) are characterized by clonal proliferation of hematopoietic stem/progenitor cells and their apoptosis, and show a propensity to progress to acute myelogenous leukemia (AML). Although MDS are recognized as neoplastic ... ...

    Abstract Myelodysplastic syndromes (MDS) are characterized by clonal proliferation of hematopoietic stem/progenitor cells and their apoptosis, and show a propensity to progress to acute myelogenous leukemia (AML). Although MDS are recognized as neoplastic diseases caused by genomic aberrations of hematopoietic cells, the details of the genetic abnormalities underlying disease development have not as yet been fully elucidated due to difficulties in analyzing chromosomal abnormalities. Recent advances in comprehensive analyses of disease genomes including whole-genome sequencing technologies have revealed the genomic abnormalities in MDS. Surprisingly, gene mutations were found in approximately 80-90% of cases with MDS, and the novel mutations discovered with these technologies included previously unknown, MDS-specific, mutations such as those of the genes in the RNA-splicing machinery. It is anticipated that these recent studies will shed new light on the pathophysiology of MDS due to genomic aberrations.
    MeSH term(s) Chromosome Aberrations ; Chromosomes, Human ; Epigenesis, Genetic ; Genome, Human ; Genomics ; High-Throughput Nucleotide Sequencing ; Humans ; Mutation ; Myelodysplastic Syndromes/genetics
    Language Japanese
    Publishing date 2016
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 390900-1
    ISSN 0485-1439
    ISSN 0485-1439
    DOI 10.11406/rinketsu.57.1972
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1175: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 535: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: [Risk-stratified treatment strategy for myelodysplastic syndromes].

    Ichikawa, Motoshi

    Rinsho ketsueki] The Japanese journal of clinical hematology

    2012  Volume 53, Issue 10, Page(s) 1509–1515

    MeSH term(s) Humans ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/therapy ; Practice Guidelines as Topic/standards ; Risk Factors ; Severity of Illness Index
    Language Japanese
    Publishing date 2012-10
    Publishing country Japan
    Document type Journal Article ; Review
    ZDB-ID 390900-1
    ISSN 0485-1439
    ISSN 0485-1439
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1175: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 535: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: [COVID-19 development during the treatment of paroxysmal nocturnal hemoglobinuria].

    Shino, Masahiro / Iizuka, Hiromitsu / Fukushima, Hidehito / Takeyasu, Sho / Kamoda, Yoshimasa / Kida, Michiko / Ichikawa, Motoshi / Anazawa, Rie / Sakurai, Takayuki / Usuki, Kensuke

    Rinsho ketsueki] The Japanese journal of clinical hematology

    2023  Volume 64, Issue 3, Page(s) 224–229

    Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder in which an activated complement causes intravascular hemolysis of erythrocytes that do not have complement regulators. It is critical to monitor the rapid progression of hemolysis caused by ... ...

    Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder in which an activated complement causes intravascular hemolysis of erythrocytes that do not have complement regulators. It is critical to monitor the rapid progression of hemolysis caused by infection and thrombosis. As far as we can tell, this is the first report of 5 COVID-19 patients with PNH in Japan. Three patients were being treated with ravulizumab, one with eculizumab, and one with crovalimab. All five cases had received two or more COVID-19 vaccinations. COVID-19 was classified as mild in four cases and moderate in one. None of the cases required the use of oxygen, and none became severe. All of them experienced breakthrough hemolysis, and two required red blood cell transfusions. In any case, no thrombotic complications were observed.
    MeSH term(s) Humans ; Hemoglobinuria, Paroxysmal/therapy ; Hemolysis ; COVID-19 ; Antibodies, Monoclonal ; Erythrocytes ; Thrombosis
    Chemical Substances Antibodies, Monoclonal
    Language Japanese
    Publishing date 2023-03-13
    Publishing country Japan
    Document type English Abstract ; Journal Article
    ZDB-ID 390900-1
    ISSN 0485-1439
    ISSN 0485-1439
    DOI 10.11406/rinketsu.64.224
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1175: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 535: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Essential thrombocythaemia with aggressive megakaryocytosis after myelofibrotic transformation.

    Sasaki, Ko / Nannya, Yasuhito / Nakamura, Yuko / Ichikawa, Motoshi / Ogawa, Seishi / Mitani, Kinuko

    Hematology (Amsterdam, Netherlands)

    2021  Volume 26, Issue 1, Page(s) 594–600

    Abstract: Background: Among myeloproliferative neoplasms, it is often difficult to distinguish essential thrombocythaemia (ET) from prefibrotic-stage primary myelofibrosis (PMF) with thrombocytosis given their overlapping clinicopathological phenotypes.: Case ... ...

    Abstract Background: Among myeloproliferative neoplasms, it is often difficult to distinguish essential thrombocythaemia (ET) from prefibrotic-stage primary myelofibrosis (PMF) with thrombocytosis given their overlapping clinicopathological phenotypes.
    Case presentation: We encountered a 45-year-old male who was initially diagnosed with ET and eventually became transformed to secondary myelofibrosis 20 years later. Two distinct types of aberrant megakaryocytes were observed at diagnosis: one type characteristic of ET and the other type characteristic of PMF. With a proliferation in the bone marrow, aberrant megakaryocytes were infiltrated into the extramedullary organs and were even present in the thrombus were observed at autopsy. As a result of next-generation sequencing, the significant increase of variant allele frequency (VAF) of
    Conclusions: This patient could be recognized as an atypical case of aggressive megakaryocytosis transformed from ET.
    MeSH term(s) Bone Marrow/pathology ; Humans ; Male ; Megakaryocytes/pathology ; Middle Aged ; Primary Myelofibrosis/complications ; Primary Myelofibrosis/diagnosis ; Primary Myelofibrosis/pathology ; Thrombocythemia, Essential/complications ; Thrombocythemia, Essential/diagnosis ; Thrombocythemia, Essential/pathology
    Language English
    Publishing date 2021-08-17
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 1341428-8
    ISSN 1607-8454 ; 1024-5332 ; 1024-5340
    ISSN (online) 1607-8454
    ISSN 1024-5332 ; 1024-5340
    DOI 10.1080/16078454.2021.1965714
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4538: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Suicide attempt induced by drug-induced leukoencephalopathy: A case report.

    Maehara, Ryo / Kawamata, Yasushi / Ichikawa, Motoshi / Mitani, Kinuko / Yasui-Furukori, Norio / Shimoda, Kazutaka

    Neuropsychopharmacology reports

    2021  Volume 41, Issue 4, Page(s) 551–553

    Abstract: Background: Leukoencephalopathy is identified during the administration of anticancer drugs. Symptoms vary from neurological symptoms to psychiatric symptoms depending on the site of damage. There have been no previous reports of suicide attempts due to ...

    Abstract Background: Leukoencephalopathy is identified during the administration of anticancer drugs. Symptoms vary from neurological symptoms to psychiatric symptoms depending on the site of damage. There have been no previous reports of suicide attempts due to drug-induced leukoencephalopathy.
    Case presentation: The patient was diagnosed with diffuse large B-cell lymphoma (DLBCL) infiltrating the pharyngeal lesion. Rituximab + methotrexate + oncovin + procarbazine (R-MPV) therapy, a methotrexate-containing chemotherapy, was initiated. At the end of the fifth course, the patient attempted suicide by hanging with an appliance cord, which was associated with delusion. A head MRI scan showed no evidence of lymphoma recurrence, but white matter lesions around the ventricles showed progression.
    Conclusion: We report the case of a patient in whom drug-induced leukoencephalopathy related to methotrexate led to a suicide attempt. In addition to monitoring brain tumors, daily monitoring of psychiatric and neurological symptoms is important for patients with methotrexate-induced encephalopathy.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Leukoencephalopathies/chemically induced ; Leukoencephalopathies/diagnostic imaging ; Magnetic Resonance Imaging ; Methotrexate/adverse effects ; Suicide, Attempted
    Chemical Substances Methotrexate (YL5FZ2Y5U1)
    Language English
    Publishing date 2021-10-15
    Publishing country United States
    Document type Case Reports ; Journal Article
    ISSN 2574-173X
    ISSN (online) 2574-173X
    DOI 10.1002/npr2.12214
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article ; Online: Postoperative Pleurosubcutaneous Fistula with a Thoracic Lump.

    Yaguchi, Daizo / Ichikawa, Motoshi / Kobayashi, Daisuke / Ito, Masao

    Internal medicine (Tokyo, Japan)

    2016  Volume 55, Issue 16, Page(s) 2317–2318

    Language English
    Publishing date 2016
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 32371-8
    ISSN 1349-7235 ; 0021-5120 ; 0918-2918
    ISSN (online) 1349-7235
    ISSN 0021-5120 ; 0918-2918
    DOI 10.2169/internalmedicine.55.6690
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 240: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top